Chunxiao Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chunxiao Hu has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
Bo Xu
Department of Anesthesiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi, Jiangsu 214023, China
8 shared publicationsChunlan Hu
5 shared publicationsJiaojiao Sun
Department of Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China
5 shared publicationsHuizhi Yu
4 shared publicationsJing Wang
4 shared publicationsMeng Sui
Department of Anesthesiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi, Jiangsu 214023, China
4 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Wolters Kluwer Health in Chinese Medical Journal
MOTS-c mediates remote ischemic preconditioning-induced protection against lung ischemia-reperfusion injury via NRF2-dependent mitochondrial biogenesis
Was not provided for this article.
- 21 September 2026
- Published by Wolters Kluwer Health in Chinese Medical Journal
Open AccessMOTS-c mediates remote ischemic preconditioning-induced protection against lung ischemia-reperfusion injury via NRF2-dependent mitochondrial biogenesis
Was not provided for this article.
- Open Access
- 10 August 2026
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 15, e86211
Patient-Reported Quality of Life in Lung Transplantation: Prospective Cohort Study
Background: Lung transplantation (LTx) is an established treatment for patients with end-stage lung diseases and can substantially improve survival. However, posttransplant recovery involves complex physical, psychological, and functional challenges, making quality of life (QoL) an important outcome beyond survival alone. Evidence on early longitudinal QoL changes after LTx remains limited, particularly in Chinese recipients and when assessed using disease-specific patient-reported outcome instruments. Objective: This study aimed to assess QoL and track its longitudinal changes in patients who underwent LTx using a disease-specific patient-reported outcome instrument. Methods: This single-center prospective cohort study screened 66 patients for enrollment who underwent LTx at the Xi’an Jiaotong University Lung Transplantation Center in China from June 2023 to December 2025. QoL was assessed using the Chinese version of the Lung Transplant Quality of Life questionnaire at baseline (preoperative) and serially at 1, 2, 3, 4, 5, and 6 months after surgery. The Lung Transplant Quality of Life questionnaire comprises 40 items across 7 domains, and each domain score was calculated as the item mean (range 0‐4). Random-intercept linear mixed models (LMMs) with both categorical and linear time specifications were fitted separately for each domain to evaluate longitudinal changes, accounting for repeated measures and incomplete follow-up under the missing at random assumption. Results: A total of 203 interviews from 51 eligible patients were included in this study, with a median of 5 (IQR 2-6) interviews for each patient. LMM analysis revealed significant overall time effects in 6 of 7 domains (likelihood ratio test: P <.01 in all cases). Health perceptions showed the earliest and largest improvement (LMM-adjusted mean difference [MD] −1.58 at month 6; β=−0.23 points per month; P <.001), followed by respiratory symptoms (MD −0.95 at month 6; β=−0.15 per month), anxiety and depression (MD −0.82 at month 6; β=−0.13 per month), digestive symptoms (MD −0.50 at month 6; β=−0.10 per month), and cognitive limitations (MD −0.51 at month 6; β=−0.09 per month; P <.001 in all cases). Global well-being was the only domain with a positive trajectory (MD 1.18 at month 6; β=0.13 per month; P =.002), with significant improvement already evident at month 1 (MD 0.71; P =.23). Conclusions: LTx significantly improved QoL in patients with end-stage lung diseases, with the most substantial gains in health perceptions and respiratory symptoms. Patient-reported outcome–based monitoring can capture clinically meaningful QoL changes and should be integrated into routine posttransplant care to identify critical intervention time points and optimize long-term recovery.
- 10 August 2026
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 15, e86211
Open AccessPatient-Reported Quality of Life in Lung Transplantation: Prospective Cohort Study
Background: Lung transplantation (LTx) is an established treatment for patients with end-stage lung diseases and can substantially improve survival. However, posttransplant recovery involves complex physical, psychological, and functional challenges, making quality of life (QoL) an important outcome beyond survival alone. Evidence on early longitudinal QoL changes after LTx remains limited, particularly in Chinese recipients and when assessed using disease-specific patient-reported outcome instruments. Objective: This study aimed to assess QoL and track its longitudinal changes in patients who underwent LTx using a disease-specific patient-reported outcome instrument. Methods: This single-center prospective cohort study screened 66 patients for enrollment who underwent LTx at the Xi’an Jiaotong University Lung Transplantation Center in China from June 2023 to December 2025. QoL was assessed using the Chinese version of the Lung Transplant Quality of Life questionnaire at baseline (preoperative) and serially at 1, 2, 3, 4, 5, and 6 months after surgery. The Lung Transplant Quality of Life questionnaire comprises 40 items across 7 domains, and each domain score was calculated as the item mean (range 0‐4). Random-intercept linear mixed models (LMMs) with both categorical and linear time specifications were fitted separately for each domain to evaluate longitudinal changes, accounting for repeated measures and incomplete follow-up under the missing at random assumption. Results: A total of 203 interviews from 51 eligible patients were included in this study, with a median of 5 (IQR 2-6) interviews for each patient. LMM analysis revealed significant overall time effects in 6 of 7 domains (likelihood ratio test: P <.01 in all cases). Health perceptions showed the earliest and largest improvement (LMM-adjusted mean difference [MD] −1.58 at month 6; β=−0.23 points per month; P <.001), followed by respiratory symptoms (MD −0.95 at month 6; β=−0.15 per month), anxiety and depression (MD −0.82 at month 6; β=−0.13 per month), digestive symptoms (MD −0.50 at month 6; β=−0.10 per month), and cognitive limitations (MD −0.51 at month 6; β=−0.09 per month; P <.001 in all cases). Global well-being was the only domain with a positive trajectory (MD 1.18 at month 6; β=0.13 per month; P =.002), with significant improvement already evident at month 1 (MD 0.71; P =.23). Conclusions: LTx significantly improved QoL in patients with end-stage lung diseases, with the most substantial gains in health perceptions and respiratory symptoms. Patient-reported outcome–based monitoring can capture clinically meaningful QoL changes and should be integrated into routine posttransplant care to identify critical intervention time points and optimize long-term recovery.
- Open Access
- 10 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2075
A Decade of Lung Transplantation in China (2015–2024): Driving Quality Improvement and Scale Expansion Through Management Systems
Since organ donation after citizen death became the sole legal source in 2015, lung transplantation (LTx) in China has undergone a systematic transformation, shifting from numerical scarcity to scale expansion and from technical exploration to sustained improvement in quality. From a management perspective, this article provides a comprehensive review of the development of LTx in China between 2015 and 2024, demonstrating that its central achievement has been the establishment of an integrated management system that combines national top-level policy design, standardized and homogeneous training, multidisciplinary collaboration, standardized clinical pathways, and rigorous quality assessment. Supported by a mechanism based on data-driven decision making, standard-guided implementation, and closed-loop management, this system has effectively ensured quality homogeneity and controllable risk during the dissemination of advanced transplantation techniques. Over the past decade, the number of hospitals performing LTx increased from 9 to 45, annual procedure volume rose from 118 to 925 cases, and the cumulative total of completed LTx was 5483. During the same period, 30-day survival improved from 78.5% to 85.3%. This system-oriented management model provides an important reference for the global community, particularly for developing countries facing challenges related to resource imbalance, by demonstrating how institutional innovation can facilitate the safe and efficient dissemination of highly complex medical technologies.
- 10 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2075
Open AccessA Decade of Lung Transplantation in China (2015–2024): Driving Quality Improvement and Scale Expansion Through Management Systems
Since organ donation after citizen death became the sole legal source in 2015, lung transplantation (LTx) in China has undergone a systematic transformation, shifting from numerical scarcity to scale expansion and from technical exploration to sustained improvement in quality. From a management perspective, this article provides a comprehensive review of the development of LTx in China between 2015 and 2024, demonstrating that its central achievement has been the establishment of an integrated management system that combines national top-level policy design, standardized and homogeneous training, multidisciplinary collaboration, standardized clinical pathways, and rigorous quality assessment. Supported by a mechanism based on data-driven decision making, standard-guided implementation, and closed-loop management, this system has effectively ensured quality homogeneity and controllable risk during the dissemination of advanced transplantation techniques. Over the past decade, the number of hospitals performing LTx increased from 9 to 45, annual procedure volume rose from 118 to 925 cases, and the cumulative total of completed LTx was 5483. During the same period, 30-day survival improved from 78.5% to 85.3%. This system-oriented management model provides an important reference for the global community, particularly for developing countries facing challenges related to resource imbalance, by demonstrating how institutional innovation can facilitate the safe and efficient dissemination of highly complex medical technologies.
- Open Access
- 10 February 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Anesthesia practices for lung transplantation in China: a nationwide survey
Limited information is available regarding the current state of anesthetic practices in lung transplantation (LTx) anesthesia across China. A nationwide qu
- 10 February 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Open AccessAnesthesia practices for lung transplantation in China: a nationwide survey
Limited information is available regarding the current state of anesthetic practices in lung transplantation (LTx) anesthesia across China. A nationwide qu
- Open Access
- 12 January 2026
- Published by Elsevier in Redox Biology
- Vol. 90, 104016
Unveiling a novel function of Aconitase-2: attenuating lung ischemia-reperfusion injury via inhibition of pulmonary endothelial apoptosis
- 12 January 2026
- Published by Elsevier in Redox Biology
- Vol. 90, 104016
Open AccessUnveiling a novel function of Aconitase-2: attenuating lung ischemia-reperfusion injury via inhibition of pulmonary endothelial apoptosis
- 1 January 2026
- Published by World Journal of Emergency Medicine in World Journal of Emergency Medicine
- Vol. 17 (3) , 209-214
Consensus on the use of extracorporeal membrane oxygenation during the perioperative period of lung transplantation
- 1 January 2026
- Published by World Journal of Emergency Medicine in World Journal of Emergency Medicine
- Vol. 17 (3) , 209-214
Consensus on the use of extracorporeal membrane oxygenation during the perioperative period of lung transplantation
- Open Access
- 1 November 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (11) , 10324-10336
Impact of preoperative left ventricular diastolic dysfunction on primary graft dysfunction and mortality following lung transplantation
Background: Lung transplantation (LTx) is a definitive treatment for end-stage lung disease, yet primary graft dysfunction (PGD) remains a major cause of early postoperative morbidity and mortality. Left ventricular diastolic dysfunction (LVDD) is common in these patients, but its impact on PGD and survival remains unclear. This study aimed to determine whether preoperative LVDD increases the risk of PGD and 1-year mortality after LTx. Methods: A retrospective cohort study was conducted, involving 344 patients who underwent LTx in Wuxi People’s Hospital from January 1, 2018, to June 22, 2021. Regression models were utilized to examine the effects of LVDD and transthoracic echocardiography (TTE) parameters on PGD or 1-year mortality risk. The predictive performance of various cardiac indicators for PGD was evaluated using the area under the curve (AUC). Results: LVDD [odds ratio (OR) 2.099, 95% confidence interval (CI) 1.071–4.116, P=0.03] and e’Conclusions: Preoperative LVDD significantly increases the risk of PGD following LTx. LVDD was not an independent risk factor for postoperative 1-year mortality. Future prospective clinical studies are required to validate LVDD as a risk factor for post-LTx PGD and to further investigate whether LVDD impacts mortality through mediator effects.
- 1 November 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (11) , 10324-10336
Open AccessImpact of preoperative left ventricular diastolic dysfunction on primary graft dysfunction and mortality following lung transplantation
Background: Lung transplantation (LTx) is a definitive treatment for end-stage lung disease, yet primary graft dysfunction (PGD) remains a major cause of early postoperative morbidity and mortality. Left ventricular diastolic dysfunction (LVDD) is common in these patients, but its impact on PGD and survival remains unclear. This study aimed to determine whether preoperative LVDD increases the risk of PGD and 1-year mortality after LTx. Methods: A retrospective cohort study was conducted, involving 344 patients who underwent LTx in Wuxi People’s Hospital from January 1, 2018, to June 22, 2021. Regression models were utilized to examine the effects of LVDD and transthoracic echocardiography (TTE) parameters on PGD or 1-year mortality risk. The predictive performance of various cardiac indicators for PGD was evaluated using the area under the curve (AUC). Results: LVDD [odds ratio (OR) 2.099, 95% confidence interval (CI) 1.071–4.116, P=0.03] and e’Conclusions: Preoperative LVDD significantly increases the risk of PGD following LTx. LVDD was not an independent risk factor for postoperative 1-year mortality. Future prospective clinical studies are required to validate LVDD as a risk factor for post-LTx PGD and to further investigate whether LVDD impacts mortality through mediator effects.
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 7544-7558
Duration of extracorporeal membrane oxygenation support and survival outcomes: a retrospective analysis for lung transplant recipients with idiopathic pulmonary fibrosis
Background: Lung transplantation (LTx) is the only effective treatment for patients with end-stage idiopathic pulmonary fibrosis (IPF). However, little is known about the effect of extracorporeal membrane oxygenation (ECMO) on the prognosis of these patients. This study aimed to explore the association between ECMO duration and survival outcomes in IPF patients undergoing LTx. Methods: This was a single-center retrospective cohort study that included 276 IPF patients who underwent LTx at the Affiliated Wuxi People’s Hospital of Nanjing Medical University China, between January 2015 and December 2020. The primary outcome was overall survival (OS). Several Cox proportional hazards regression models with a cubic spline function were established to analyze the association between ECMO duration and mortality. Results: Among the 276 recipients, the median duration of ECMO was 24 hours [interquartile range (IQR): 7.25–40.0 hours], with 80 (29.0%) receiving veno-arterial (VA) ECMO support, 149 (54.0%) receiving veno-venous (VV) ECMO support, and 47 (17.0%) not receiving any ECMO support. There was no statistically significant difference in cumulative survival among the ECMO support strategies (P=0.44). The main model showed a 13% increase in mortality risk for each additional day of ECMO use [hazard ratio (HR) =1.13, 95% confidence interval (CI): 1.07–1.20, PConclusions: In IPF patients receiving LTx, ECMO duration demonstrates a strong nonlinear association with mortality. Longer duration of ECMO support serves as a robust indicator of underlying disease severity and postoperative complications predicting poor outcomes. The identified thresholds (0.8 and 5.54 days) provide clinically relevant markers for risk stratification and prognostication. Future prospective studies are needed to validate these inflection points and clarify interactions between ECMO duration, patient factors, and outcomes.
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 7544-7558
Open AccessDuration of extracorporeal membrane oxygenation support and survival outcomes: a retrospective analysis for lung transplant recipients with idiopathic pulmonary fibrosis
Background: Lung transplantation (LTx) is the only effective treatment for patients with end-stage idiopathic pulmonary fibrosis (IPF). However, little is known about the effect of extracorporeal membrane oxygenation (ECMO) on the prognosis of these patients. This study aimed to explore the association between ECMO duration and survival outcomes in IPF patients undergoing LTx. Methods: This was a single-center retrospective cohort study that included 276 IPF patients who underwent LTx at the Affiliated Wuxi People’s Hospital of Nanjing Medical University China, between January 2015 and December 2020. The primary outcome was overall survival (OS). Several Cox proportional hazards regression models with a cubic spline function were established to analyze the association between ECMO duration and mortality. Results: Among the 276 recipients, the median duration of ECMO was 24 hours [interquartile range (IQR): 7.25–40.0 hours], with 80 (29.0%) receiving veno-arterial (VA) ECMO support, 149 (54.0%) receiving veno-venous (VV) ECMO support, and 47 (17.0%) not receiving any ECMO support. There was no statistically significant difference in cumulative survival among the ECMO support strategies (P=0.44). The main model showed a 13% increase in mortality risk for each additional day of ECMO use [hazard ratio (HR) =1.13, 95% confidence interval (CI): 1.07–1.20, PConclusions: In IPF patients receiving LTx, ECMO duration demonstrates a strong nonlinear association with mortality. Longer duration of ECMO support serves as a robust indicator of underlying disease severity and postoperative complications predicting poor outcomes. The identified thresholds (0.8 and 5.54 days) provide clinically relevant markers for risk stratification and prognostication. Future prospective studies are needed to validate these inflection points and clarify interactions between ECMO duration, patient factors, and outcomes.
- 17 January 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 229, 127-138
MOTS-c mimics remote ischemic preconditioning in protecting against lung ischemia-reperfusion injury by alleviating endothelial barrier dysfunction
- 17 January 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 229, 127-138
MOTS-c mimics remote ischemic preconditioning in protecting against lung ischemia-reperfusion injury by alleviating endothelial barrier dysfunction